Answers are grounded in this paper and cite their sources.
The incorporation of a second metal center with different biological targets and complementary physicochemical properties into metal-based compounds represents a promising strategy to enhance anticancer efficacy and overcome the limitations of conventional monometallic drugs. In recent years, increasing attention has been devoted to multitarget anticancer agents, including heterometallic complexes. This review provides an overview of recent advances in Group 8 bimetallic complexes containing iron, ruthenium, or osmium for light-driven cancer therapy. Particular emphasis is placed on their molecular design, photophysical and photochemical properties, mechanisms of action, and anticancer activity. The influence of the two metal centers on photoactivation, generation of reactive species, cellular targets, and therapeutic efficacy is discussed, together with emerging structure–activity relationships. Finally, current challenges and future perspectives for the development of these complexes as photoactivated anticancer agents are highlighted.
No takes yet. Share an insight, caveat, or question.
Martínez-Alonso et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: